Aspira Women’s Health develops and commercializes testing options for women’s gynecological health, beginning with ovarian cancer.
Aspira markets its ovarian cancer risk assessment portfolio to healthcare providers as OvaSuite. Aspira’s non-invasive endometriosis diagnostic test, EndoCheck, is in development.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
OvaWatch is intended for initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses when surgery may be premature or unnecessary.
Source: LinkedIn company description · Retrieved October 13, 2026
Ova1Plus combines Ova1 and Overa to detect ovarian malignancy risk in women with adnexal masses planned for surgery.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
Open the published source list.RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 2, 2026, September 18, 2026, September 19, 2026 and September 30, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.